When n=1 is not enough. An initial take on the Libre2 and Libre2 Plus comparison
As I mentioned a couple of weeks ago, I received a number of Libre2 and Libre2 Plus devices to try. So far, I’ve only used […]
Abbott
Welcome to the Wild, Wild West: the CGM head-to-head study
In the past at Diabettech, we’ve talked about how the design of a CGM safety and accuracy study plays a big part in the results […]
A lesson in how not to roll out real-time CGM to an existing system
What impact does a botched rollout of an app update have on a CGM provider?
The art of CGM accuracy studies, part 2: The Freestyle Libre3
As I’m currently testing a Libre3, and have taken a look back at the various accuracy studies as a part of this to review MARD data, […]
Comparing the Libre2 and Dexcom G6 as RT-CGM using #WeAreNotWaiting software
The Libre2 has been available for some time now in both Germany and Norway, and is used by a reasonable number of loopers to drive […]
#FreestyleLibre & #MiaoMiao: Two weeks. What did I think?
After running with the FreeStyle Libre with the MiaoMiao as a CGM system for two weeks, I’ve drawn some conclusions from use, although there’s a […]
Death or profit: Flash, CGM and patient-centricity
As many people with T1D in the UK will know, there has been an ongoing dialogue between NHS England and the DVLA with respect to […]
#FreeStyleLibre2 – further thoughts
The big question that remains for many more technical users in relation to the FreeStyle Libre 2 is whether it is transmitting glucose data or […]
The Abbott Freestyle Libre will be available on the NHS. What does that mean?
If you live in the Social Media bubble for T1D in the UK, you can’t fail to have noticed that there was a press release […]
Abbott’s #FreestyleLibre – disrupting and democratising Diabetes care in Europe
A little over two years ago, the Abbott Freestyle Libre launched, to much fanfare and significant consumer trialling and direct patient marketing (anyone see a […]